Fort Washington Investment Advisors Inc. OH Boosts Stake in Haemonetics Co. (NYSE:HAE)

Fort Washington Investment Advisors Inc. OH raised its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 88.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 517,086 shares of the medical instruments supplier's stock after purchasing an additional 242,956 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 1.03% of Haemonetics worth $32,861,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HAE. TD Waterhouse Canada Inc. bought a new position in shares of Haemonetics during the fourth quarter valued at about $25,000. Covestor Ltd grew its stake in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the period. Whittier Trust Co. purchased a new stake in shares of Haemonetics during the 4th quarter valued at $62,000. Parkside Financial Bank & Trust raised its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

HAE stock traded down $0.22 during midday trading on Thursday, reaching $71.29. 368,555 shares of the company's stock traded hands, compared to its average volume of 678,186. The firm has a market capitalization of $3.42 billion, a PE ratio of 28.07, a price-to-earnings-growth ratio of 1.11 and a beta of 0.36. The company has a 50-day moving average price of $64.63 and a two-hundred day moving average price of $69.42. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $94.99. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The firm's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.90 EPS. As a group, equities analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the subject of a number of research analyst reports. Raymond James restated a "strong-buy" rating and set a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Needham & Company LLC decreased their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.